Ticker LaunchIPO · NRXS
Neuraxis, INC
Neuraxis, INC (NRXS) priced its initial public offering on Aug 11, 2023 at $6.00 per share, and listed on NYSE American. At the IPO price its market capitalization was about $36.8M. Lucosky Brookman advised the company and Carmel, Milazzo & Feil advised the underwriters.
Neuraxis, Inc. is a medical technology company developing neuromodulation therapies for chronic conditions in children and adults. Its IB-Stim device, based on its PENFS technology, has FDA clearance for functional abdominal pain associated with IBS in patients aged 11 to 18.
- Status
- IPO
- Ticker
- NRXS
- Exchange
- NYSE American
- Priced
- Aug 11, 2023
- IPO price
- $6.00
- Market cap at IPO price
- $36.8M
- First filed
- Jan 10, 2023
- Company counsel
- Lucosky Brookman
- Underwriters' counsel
- Carmel, Milazzo & Feil
- Sector
- Healthcare
- Country / state
- IN
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jan 10, 2023
- Latest amendment Jul 28, 2023
- Final prospectus (424B4) Aug 11, 2023
- All filings on EDGAR CIK 1933567
Other Healthcare IPOs in 2023
- Pixie Dust Technologies, Inc.Aug 2, 2023 · $15M
- Jin Medical International Ltd.ZJYL · Mar 29, 2023 · $8M